A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease COPD Patients Managed with Aerobika OPEPReport as inadecuate




A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease COPD Patients Managed with Aerobika OPEP - Download this document for free, or read online. Document in PDF available to download.

Pulmonary Therapy

, Volume 3, Issue 1, pp 163–171

First Online: 06 February 2017Received: 04 January 2017DOI: 10.1007-s41030-017-0027-5

Cite this article as: Burudpakdee, C., Seetasith, A., Dunne, P. et al. Pulm Ther 2017 3: 163. doi:10.1007-s41030-017-0027-5

Abstract

IntroductionOscillating positive expiratory pressure OPEP devices may reduce chronic symptoms in patients with obstructive pulmonary disease COPD; however, no real-world studies have been performed to evaluate the benefits of these devices. The objective of this study was to measure the rate of early 30-day moderate-to-severe exacerbations and related costs in COPD patients treated with Aerobika, an OPEP device, vs. a matched control group in a real-world setting.

MethodsThe study utilized data from the QuintilesIMS’ CDM hospital database. COPD patients treated with Aerobika OPEP between 9-2013 and 8-2015 were propensity score matched to COPD patients who did not use any positive expiratory pressure device. Severe exacerbation was defined as a hospital admission with a diagnosis for chronic bronchitis or COPD. Moderate-to-severe exacerbation was defined as a hospitalization or an ED visit with a diagnosis for chronic bronchitis or COPD. Exacerbations and costs were compared between cohorts at 30 days. A generalized linear model GLM was used to estimate the marginal effect of Aerobika OPEP on the cost of ED visits and hospitalizations due to COPD exacerbations.

ResultsA total of 405 Aerobika OPEP patients were matched to 405 controls. At 30 days, 18.5% of subjects using the Aerobika OPEP vs. 25.7% of controls had a moderate-to-severe exacerbation p = 0.014; 13.8% of subjects with Aerobika OPEP vs. 19.0% of controls had a severe exacerbation p = 0.046. The mean per patient cost of moderate-to-severe exacerbations and severe exacerbations in the Aerobika OPEP group was significantly lower than controls $2975 vs. $6065; p = 0.008, and $2838 vs. $5871; p = 0.009, respectively. In the GLM, the per-patient cost of moderate-to-severe exacerbations in the Aerobika OPEP group was 34% lower p = 0.012 than the control group.

ConclusionsStudy findings suggest that using Aerobika OPEP as part of a treatment regimen may help reduce ED visits, hospital re-admissions and related costs in COPD patients who have a history of exacerbations.

KeywordsCOPD Exacerbations PEP OPEP Enhanced contentTo view enhanced content for this article go to http:-www.medengine.com-Redeem-E587F06068790517.

Electronic supplementary materialThe online version of this article doi:10.1007-s41030-017-0027-5 contains supplementary material, which is available to authorized users.





Author: Chakkarin Burudpakdee - Arpamas Seetasith - Patrick Dunne - Garry Kauffman - Brian Carlin - Dom Coppolo - Jason Suggett

Source: https://link.springer.com/



DOWNLOAD PDF




Related documents